Friday, August 8, 2025 8/8/2025

Pan-cancer Analysis of Convergent Immunoglobulins from Tumor-infiltrating B Cells

Award Number: R21CA297404
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2025
PERIOD OF PERFORMANCE END DATE: 07/31/2027

Group Awards By:

View Award Description

Pan-cancer Analysis of Convergent Immunoglobulins from Tumor-infiltrating B Cells - Project Summary Tumor infiltrating B cells (TIL-B) express B cell receptors (BCR) and antibodies (Abs) that can have a role in antitumor function. What tumor antigens they target can give insight into anti-tumor immune function and potentially leveraged for therapeutic strategies. Public tumor RNA-seq databases such as the TCGA, represent a wide and deep data source that include TIL-B BCRs. Our analysis of these datasets reveals the surprising finding of BCRs with the same V, J and complementarity-determining region 3 (CDR3) shared across patients. The occurrence of this phenomena by random chance is extremely rare (as low as one in 10 trillion) and therefore suggests a convergent response shared in patient tumor types. Although BCR repertoire has been analyzed in small groups of patients, a wide BCR analysis within and across tumor types has not been done. Analyzing convergent BCRs could inform what common antigen targets the immune system is focusing on. The bulk of tumor sequencing data exists as NGS RNA-seq. A challenge for reconstructing a BCR is matching the immunoglobulin heavy and light chains. To accomplish this, we have developed a comprehensive algorithm based on our Frequency Inference Model (FIM) to predict the paired heavy and light chains from sequencing datasets. We propose to refine our sequence analysis by leveraging machine learning algorithms to inform our ability to clone, produce and characterize Abs shared across patient tumor samples. This proposal will characterize antibodies reconstructed from RNA-seq datasets and test their tumor and antigen recognition characteristics. Abs will be tested for anti-tumor potential and antigen identification will be done on a small cohort with the following aims. Aim 1: Analyze immunoglobulins from different cancer types in TCGA. Convergent immunoglobulins will be identified, and matching chains identified by leveraging the deep learning algorithms. Aim 2: Produce shared Abs using the MDACC Recombinant Antibody Production Platform based on the computationally derived immunoglobulins. The reactivity to cell lines and tumor samples will be analyzed. Aim 3: Elucidate targets of TIL-Bs and their cognate BCRs and evaluate the anti-tumor function the antibodies. A pipeline to identify antigen epitopes will be used. The anti-tumor function of the antibodies will be assessed. With the completion of these aims we will have a proof-of-concept that our pipeline can recapitulate shared BCRs and assess tumor targeting potential. This platform would enable identifying shared patient antigen response that could be potentially leveraged to develop therapeutic targeting strategies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $421,685 )
2025	2025	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Biology Research	000	1	7/28/2025	NEW	$421,685
														Subtotal = $421,685

Grand Total All Awards = $421,685

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Pan-cancer Analysis of Convergent Immunoglobulins from Tumor-infiltrating B Cells

Award Number: R21CA297404

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2025

PERIOD OF PERFORMANCE END DATE: 07/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer